|
Dynamic circulating tumor DNA (ctDNA) in monitoring trastuzumab deruxtecan (TDXd) activity for patients (pts) with advanced breast cancer: Preliminary results of a feasibility study. |
| |
|
No Relationships to Disclose |
| |
|
Speakers' Bureau - Amgen; MSD; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Novartis |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Speakers' Bureau - Daiichi Sankyo; Lilly; Novartis |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Roche |
Research Funding - AstraZeneca (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro |
Speakers' Bureau - Clovis Oncology; MSD |
| |
|
Research Funding - Roche (Inst) |
| |
|
No Relationships to Disclose |